Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial
Authors:
- Narawitch SompornpailinNSNarawitch Sompornpailin
- Thiti SusiriwatananontTSThiti Susiriwatananont
- Virote SriuranpongVSVirote Sriuranpong
- Suebpong TanasanvimonSTSuebpong Tanasanvimon
- Chanida VinayanuwattikunCVChanida Vinayanuwattikun
- Piyada SitthideatphaiboonPSPiyada Sitthideatphaiboon
- Nattaya PoovorawanNPNattaya Poovorawan
- Nattaya TeeyapunNTNattaya Teeyapun
- Nicha ZungsontipornNZNicha Zungsontiporn
- Nussara PakvisalNPNussara Pakvisal
- Poonnakarn PanjasriprakarnPPPoonnakarn Panjasriprakarn
- Bussaba TrakarnsangaBTBussaba Trakarnsanga
Open Access
- 1 June 2026
- journal article
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e86149
Abstract
Background: Chemotherapy-related toxicities often lead to unscheduled health care use and diminished quality of life. Digital health interventions, such as chatbots, offer a scalable solution for supportive care; however, evidence regarding their effectiveness in resource-limited, low- and middle-income settings remains limited. Objective: This study aimed to evaluate the feasibility, use, and preliminary effectiveness of a closed-loop chatbot (ChulaCancer Chatbot) in reducing unscheduled hospital visits and stabilizing quality of life among patients receiving chemotherapy for breast or colorectal cancer. Methods: This pilot randomized controlled trial enrolled 40 patients at a single academic center in Thailand, randomized 1:1 to either ChulaCancer chatbot plus usual care or usual care alone. The primary end point was the proportion of unscheduled hospital visits due to chemotherapy-related toxicities within 12 weeks of treatment initiation. Secondary end points included longitudinal quality of life changes (30-item EORTC Quality of Life Questionnaire) measured at baseline, following chemotherapy cycle 2, and following cycle 4. Use metrics were extracted from the chatbot platform. Data were analyzed using the Fisher exact test and linear mixed-effects models. Results: The platform recorded 2393 total messages with a 70.5% (503/713) successful response rate for user-initiated queries. Unscheduled hospital visits occurred in 15% (3/20) of the chatbot group compared to 35% (7/20) of the usual care group (P=.24). While infection-related visits were similar between groups, the usual care group recorded multiple visits for low-acuity symptoms (eg, anxiety, headache, and edema) that were absent in the chatbot group. Regarding quality of life, the chatbot group demonstrated a significant mitigation of cancer-related fatigue following cycle 4 compared with the usual care group (P=.02 between groups). Additionally, the chatbot group significantly improved in global health status (P=.04) and avoided the decline in physical functioning observed in the control arm (P=.04). Conclusions: The integration of a closed-loop chatbot into oncology care is feasible and provides a potential secure triage mechanism that may reduce acute care use for low-acuity concerns. Future large-scale trials incorporating agentic artificial intelligence are warranted to further validate clinical and economic benefits. Trial Registration: Thai Clinical Trials Registry TCTR20251220014; https://tinyurl.com/5b6k3e63Keywords
All Related Versions
This publication has 13 references indexed in Scilit:
- The role of agentic artificial intelligence in healthcare: a scoping reviewnpj Digital Medicine, 2026
- AI agent in healthcare: applications, evaluations, and future directionsnpj Artificial Intelligence, 2026
- Feasibility of a Text Messaging–Integrated and Chatbot-Interfaced Self-Management Program for Symptom Control in Patients With Gastrointestinal Cancer Undergoing Chemotherapy: Pilot Mixed Methods StudyJMIR Formative Research, 2023
- Using a chatbot to reduce emergency department visits and unscheduled hospitalizations among patients with gynecologic malignancies during chemotherapy: A retrospective cohort studyHeliyon, 2023
- Patient Understanding of Chemotherapy and Goals of Care as Provided by Different Care Team MembersJournal of Cancer Education, 2023
- Chatbot for Health Care and Oncology Applications Using Artificial Intelligence and Machine Learning: Systematic ReviewJMIR Cancer, 2021
- Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysisClinical and Translational Oncology, 2020
- Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based studyThe Lancet Oncology, 2019
- Digitally Recorded Education: Effects on Anxiety and Knowledge Recall in Patients Receiving First-Time ChemotherapyClinical Journal of Oncology Nursing, 2018
- The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation Study of the Thai VersionQuality of Life Research, 2006